SLC5A2 and hydrops fetalis: While recent studies using new agents, such as sodium glucose cotransporter-2 inhibitors, have shown improved HF outcomes, the effects demonstrated have not been explained by improved glycemic control and other studies have shown no improvement in HF outcomes with better glycemic control [32], [33].